Results of an in vivo mouse colorectal cancer model study have shown a 60% life extension for Oxford Drug Design’s first-in-class approach against multiple tumours. 

The results follow previous in vivo validation of the therapeutic candidates and have led to an expanded mouse study which is currently under way and the company says is showing positive progress. 

Dr Paul Finn, CSO of Oxford Drug Design, said: “Our leading integrated expertise in generative AI and tRNA-synthetase drug discovery continues to produce breakthrough novel lead series efficiently and effectively, of which the progress in our oncology programme is the latest example. Our rapidly advancing efforts are now focused on bringing this potentially superior first-in-class treatment into the clinic.” 

Oxford Drug Design’s discovery platform integrates generative AI with tRNA synthetase, including proprietary structural biology. 

The approach is based on the novel target leucyl-tRNA synthetase, belonging to the tRNA synthetase enzyme family. The lead candidates are part of the company’s portfolio of new chemical scaffolds which have shown broad activity against the enzyme class. 

Dr Alan Roth, CEO of Oxford Drug Design, added: “This new milestone for Oxford Drug Design is a testament not only to the accuracy and reliability of our computational platform, SynthAI, but also to the expertise of our team. We continue to produce innovative molecules fulfilling three key metrics: they possess the required biological activity against disease, can be made using known chemical processes, and can be produced at scale. This improved accuracy is saving valuable resources and accelerating our drug candidates towards patients and their physicians.” 

 Diana Spencer, Senior Digital Content Editor, DDW